ThinkPatternGet the app
Story
BUSINESS · NOV 18, 2026

Teva Pharmaceutical R&D Chief Eric Hughes Departs Company

Teva Pharmaceutical Industries Ltd. announced that R&D chief Eric Hughes is leaving the company for an external opportunity, appointing David Gardiner as transition lead.

Teva Pharmaceutical Industries Ltd. announced that Dr. Eric Hughes, Executive Vice President of Global R&D and Chief Medical Officer, is leaving the company to pursue an external opportunity. Hughes will remain in his position for several months to facilitate a smooth transition of leadership.

CEO Richard Francis appointed David Gardiner, the Head of Innovative Medicines & Clinical Development, as the transition lead for R&D. Gardiner will report directly to Francis while the company conducts a search for a permanent successor.

Teva stated that the leadership change will not alter its R&D priorities or its Pivot to Growth strategy. The company maintains its target of generating 6-7 billion dollars in innovative medicines revenue by 2030.


Reported across 3 outlets
Actors
Teva Pharmaceutical Industries Ltd.Eric HughesRichard FrancisDavid Gardiner

Keep reading in the app

The full story and every source, free in the app.